Cautiously Optimistic: Geron’s Strategic Changes and Growth Prospects Support Buy Rating

Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on Geron. The associated price target remains the same with $3.00.

Faisal Khurshid has given his Buy rating due to a combination of factors surrounding Geron’s current market position and future prospects. The company is expected to report second-quarter earnings with Rytelo net revenues slightly exceeding consensus estimates, indicating potential growth. Despite challenges in the drug’s launch, there is optimism that management’s recent strategic changes, including leadership turnover and sales force expansion, could revitalize growth in the latter half of the year.
Additionally, while there are concerns about Rytelo’s market performance and toxicity issues, the current valuation of Geron suggests limited downside risk. The anticipation of management’s re-engagement with investors and their plans to address the initial launch struggles further supports the Buy rating. Overall, the combination of these elements suggests a cautiously optimistic outlook for Geron’s stock performance.

Khurshid covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, aTyr Pharma, and Trevi Therapeutics. According to TipRanks, Khurshid has an average return of 30.7% and a 57.61% success rate on recommended stocks.

In another report released today, Barclays also maintained a Buy rating on the stock with a $4.00 price target.